SLS Earnings — SELLAS Life Sciences Group, Inc. Common Stock Post-ER Performance | BigEarnings
SLS — SELLAS Life Sciences Group, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$8.58
Market Cap$1.6B
P/E—
52W Range— – —
Next Earnings2026-08-11
About SELLAS Life Sciences Group, Inc. Common Stock
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
